Meet Lori: Finding freedom and balance in the Parkinson’s journey

Image of Lori, real CREXONT patient.

When Lori was diagnosed with Parkinson’s disease in her mid-50s, it wasn’t unfamiliar territory. Her mother, uncle, and brother had all lived with PD, and Lori had served as a caregiver for both her mother and brother during their most challenging years. But when it became her own reality, the path ahead still felt uncertain.

 

Born and raised on a farm in New York State, Lori developed a strong sense of independence and resilience early in life. At 21, she became a mom, later building a fulfilling career in hospital administration, software development, and the travel industry. She’s always been someone who thrives when she’s creating—whether that’s designing her wardrobe, volunteering at boxing training sessions, or making people feel seen and heard.

 

Her hobbies are just as dynamic as her professional life was: boxing three times a week, volunteering at clinics for people with disabilities, walking in senior games, and even participating in triathlons and Disney marathons for friends and causes she loves. She’s also an active patient advocate and speaker with several Parkinson’s organizations, sharing her time and voice to raise awareness and inspire others to stay involved and optimistic.

Image of Lori at an aerobics class.

But despite her positivity, Parkinson’s brought real challenges. Lori struggled with the burden of frequent dosing and meal coordination while on immediate-release medications. Dyskinesia, blood pressure fluctuations, and energy dips began to interfere with the lifestyle she loved so much. For a time, she worried that independent living might become harder to manage.

Image of Lori holding childhood photos.

That changed when Lori read about CREXONT® (carbidopa and levodopa) extended-release capsules. She brought it up to her care team and began treatment in November 2024. Since then, she says she’s noticed a real difference—not just in how she feels physically, but in how her days flow. “Before, I felt like I was constantly fighting for control,” she shares. “Now, I have the freedom to focus on the things I enjoy again—sewing, getting outside, helping others.”

Today, Lori takes CREXONT four times a day. The transition has allowed her to step away from the rigid schedule she was once tied to, and she expressed that her symptoms have become more manageable. She shared that she feels like her sleep patterns are more consistent, her mobility has improved, and most importantly, she feels more like herself again.

“I’ve always been positive and upbeat—it killed me to say I didn’t feel good,” Lori says. “Now I can genuinely say [I feel like myself again].”

She’s especially passionate about helping others with PD know they’re not alone. Lori encourages patients to seek out support programs from the PD community, stay informed, and advocate for themselves and others. Whether she’s organizing a walk, testifying on environmental policy, or talking to her local mayor about pesticide use in public spaces, she’s always working to make things better—for herself and for the PD community at large.

“Even when you feel like you can’t change everything, you can always reach someone,” she says. “That’s what keeps me going.”

Lori’s experience with CREXONT is her own and may not reflect the experience of every patient. For some patients, CREXONT may cause falling asleep during daily activities. Side effects may include nausea and anxiety. Individual results will vary. Talk to your patients to see if CREXONT is right for them. Only an HCP should assess each patient’s condition and advise them on treatment options.


IMPORTANT SAFETY INFORMATION

Indications and Usage

CREXONT® (carbidopa and levodopa) extended-release capsules for oral use is indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication in adults.

Dosage and Administration

  • Levodopa-naïve patients: Starting dose is 35 mg carbidopa/140 mg levodopa taken orally twice daily for the first three days; thereafter, dosage may be increased gradually as needed
  • For patients converting to CREXONT from immediate-release carbidopa/levodopa, dosages are not substitutable on a 1:1 basis. See full prescribing information Section 2.2 for instructions
  • For patients converting from Rytary® (carbidopa and levodopa) extended-release capsules, initiate CREXONT on an approximately 1:1 mg basis using the levodopa component for conversion
  • CREXONT may be taken up to four times daily. The maximum recommended daily dosage is 525 mg carbidopa/2100 mg levodopa
  • CREXONT may be taken with or without food. Capsules should not be chewed, divided or crushed
  • CREXONT should not be taken with alcohol

Contraindications

Nonselective MAO inhibitors.

Warnings and Precautions

  • CREXONT may cause falling asleep during activities of daily living, somnolence or dizziness. Patients should avoid activities that require alertness such as driving and operating machinery until they know how CREXONT affects them
  • It is important to avoid sudden discontinuation or rapid dose reduction to reduce the risk of withdrawal symptoms such as high fever or confusion. Patients who are discontinuing CREXONT should taper off with healthcare provider guidance
  • Consider dose reductions or stopping CREXONT in patients with hallucinations or impulse control disorders (e.g., gambling, sexual urges, or uncontrolled spending)
  • Consider dose reduction in patients with dyskinesia
  • Patients with a major psychotic disorder should not be treated with CREXONT
  • Monitor patients with a history of cardiovascular disease for cardiac function
  • Monitor patients with a history of peptic ulcer for upper GI hemorrhage
  • Monitor patients with glaucoma for increased intraocular pressure

Adverse Reactions

The most common adverse reactions (incidence ≥ 3% and greater than immediate-release CD/LD) are nausea and anxiety.

Drug Interactions

Iron salts and dopamine D2 antagonists, including metoclopramide, may reduce the effectiveness of CREXONT.

Use in Specific Populations

Pregnancy: Based on animal data, CREXONT may cause fetal harm. There are no adequate data on the developmental risk associated with the use of CREXONT in pregnant women.
Breastfeeding: The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CREXONT.
Geriatric patients: There were no differences in safety outcomes between patients less than 65 years of age, 65-75 years of age, or 75 years and older.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Specialty, a division of Amneal Pharmaceuticals, LLC at 1‑877‑835‑5472 or the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for CREXONT.

Content is for guidance only. Please use clinical judgment when prescribing CREXONT. Dosage is individualized for each patient.